Practical guidance on new pharmacovigilance legislation

INICIO/Políticas y legislación | Posted 30/09/2011 post-comment0 Post your comment

New pharmacovigilance legislation was adopted by the European Parliament and European Council in December 2010. EMA is the regulatory body responsible for implementing much of the new legislation and is developing a framework for compliance and delivery of key requirements. The legislation will be effective from July 2012.

picture 64

The new EU law aims to provide better protection for people with medical conditions and make them better informed about the use and any undesirable side effects of medicines.

According to the European Commission 5% of all hospital admissions are due to serious side effects from medicines and many more cases may be unreported. Drug side effects or adverse drug reactions (ADRs) are the fifth most common cause of death, accounting for around 200,000 deaths a year, at a cost to society of almost Euros 80 billion.

What are the changes?

The aim of the new law is to update existing EU rules to improve data collection, treatment and dissemination and better inform the public and doctors. A number of changes are proposed that will strengthen the way the safety of medicines for human use is monitored in the EU.

The legislation aims to:

 

  • make roles and responsibilities clearer
  • minimise duplication of effort
  • free up resources by rationalising and simplifying ADR reporting and periodic safety update report (PSUR) reporting
  • establish a clear legal framework for post-authorisation monitoring.

 

Implementing the new legislation

In September 2011, in order to provide guidance for drug companies to comply with the new pharmacovigilance law, the European Commission published a concept paper on implementing measures for the performance of activities related to pharmacovigilance.

The concept paper is available on the EMA website and is open for public consultation until 7 November 2011: ec.europa.eu/health/files/pharmacovigilance/2011-09_concept-paper.pdf

Related article

Pharmacovigilance legislation moves a step closer

Source: EMA

comment icon Comments (0)
Post your comment
Related content
Generic ‘skinny’ labelling under threat in the US
Label prescription drugs
INICIO/Políticas y legislación Posted 05/11/2021
Lawsuits and US$450 million payout for price fixing and delayed generics entry
34 AA010660
INICIO/Políticas y legislación Posted 29/10/2021
FDA publishes final Q&A on biosimilar development and the BPCI Act
Question-Fimea-V15E29
INICIO/Políticas y legislación Posted 15/10/2021
FDA voices concerns around drug patents and competition
Patent 1 V13E17
INICIO/Políticas y legislación Posted 08/10/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010